https://www.selleckchem.com/products/brusatol.html
BACKGROUND Autologous hematological stem cell transplantation (HSCT) is a novel therapy for systemic sclerosis (SSc) that has been validated in three randomized controlled trials. OBJECTIVES To report the first Israeli experience with HSCT for progressive SSc and review the current literature. METHODS Five SSc patients who were evaluated in our department and were treated by HSCT were included. Medical records were evaluated retrospectively. Demographic, clinical, and laboratory data were recorded. Continuous data are presented as the
Like
Comment
Share
